|
|
 |
|
Viewing report
|
|
|
|
The North America Biotechnology Sectors : A Company and Industry Analysis (October 2003)
Mergent, Oct 2003, Pages: 32
Current Environment - Key Points
- The combined total revenue of ten of the top revenue-earning biotech companies in the US in 2002 was approximately $200,348,498,000
- Although the biotech Index hit an all-time low of 464.93 in September 2002 and peaked in August 2003 at 740.84, underlining the fact that 2002 was a brutal year, there has been a rapid recovery in 2003
- Major end markets include biotech crops, which are generally accepted by American consumers, although doubt persists for Europeans; as well as the biopharmaceutical sector, which is introducing a flurry of new drugs to the healthcare industry
- Worldwide biotech merger and acquisition volume increased from $1.58 billion in 2001 to $5.22 billion in 2002 with the number of transactions increasing from 13 in 2001 to a record 18 in 2002
- Recent estimates from the Biotechnology Industry Organization indicate that biotech funding from biotech-pharma alliances exceed $5 billion a year, representing an annual growth rate of more than 40%
- Several Canadian biotech companies are changing the future landscape of the Canadian biotech industry
Despite some major successes, the main concern lies in the viability of biotech companies with less than 18 months of cash on hand
- Canadian public company revenues reached $1,466 million, up 44% over 2002
In 2002, market capitalization decreased by 31% to $8,867 million from $12,909 million in 2001
Industry Profile - Key Points
- As at mid-April, the total value of US publicly traded companies- at market prices was $206 billion
- Encouraging study results on biotech drugs, coupled with a new US Food & Drug commissioner and a general willingness to take on riskier investments, has sent biotech stocks up since the start of 2003, which bodes well for the venture capital market
- The top five US companies spent an average of $133,600 per employee on R&D, approximately 20% of their revenue, while pharmaceuticals spent only 11%
- The FDA's fiscal year 2003 budget request was $1.7 billion, a net increase of $123 million over fiscal year 2002
- In late August 2003, the World Trade Organization agreed to give poor nations greater access to inexpensive, life-saving medicine by altering international trade rules; poor countries will be able to import generic versions of expensive patented medicines, buying from countries like India and Brazil, without breaking the trade laws that protect patent rights
- Canada, ranked number two in the world, is home to an estimated 417 biotech companies with more than 6,500 products at various stages of development
- According to government statistics, Canadian companies are showing strong R&D commitment, undertaking investments of $950.5 million in 2001, up 57.3% over 1999 research and development expenditure of $604.6 million
Market Trends and Outlook - Key Points
- Genetically modified food (GM food) and agricultural biotechnology is constantly in the limelight, generating both interest and controversy, throughout the world
- With an increasing world population and a slowdown in the rate of crop improvement, biotechnology makes farming less time consuming
It also helps nations outside the US and Canada achieve results in agriculture and food production that conventional plant breeding would not allow
- Despite a difficult financing situation in 2002, the biotech sector raised more than $6 billion (including partnerships) in Q2 2003
- Information technology helps researchers to connect the different scientific disciplines involved in drug discovery
Customers who bought this item also bought
US Biotech Market Analysis
Biotech 2009-Life Sciences: Navigating the Sea Change
Understanding the Global Biotech Industry
The North America Biotechnology Sectors : A Company and Industry Analysis (August 2007)
North America Biotechnology Sectors : A Company and Industry Analysis (February 2008)
Biotech Life Sciences: A 20/20 Vision to 2020
The North America Biotechnology Sectors : A Company and Industry Analysis (February 2007)
China Biotech 2008
Booming Biotech Market in India
Indian Biotech Industry (2005)
The North America Biotechnology Sectors : A Company and Industry Analysis (September 2004)
The North America Biotechnology Sectors : A Company and Industry Analysis (April 2003)
|
|
|
|
